Oppenheimer Asset Management Inc. Takes Position in Becton, Dickinson and Company (NYSE:BDX)

Oppenheimer Asset Management Inc. purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 20,645 shares of the medical instruments supplier’s stock, valued at approximately $3,787,000.

Several other hedge funds have also recently made changes to their positions in BDX. Macquarie Group Ltd. increased its position in shares of Becton, Dickinson and by 16.0% in the fourth quarter. Macquarie Group Ltd. now owns 67,709 shares of the medical instruments supplier’s stock worth $11,209,000 after buying an additional 9,340 shares during the period. Raymond James Trust N.A. increased its position in shares of Becton, Dickinson and by 3.5% in the first quarter. Raymond James Trust N.A. now owns 5,846 shares of the medical instruments supplier’s stock worth $1,073,000 after buying an additional 200 shares during the period. First National Bank of Mount Dora Trust Investment Services increased its position in shares of Becton, Dickinson and by 23.7% in the first quarter. First National Bank of Mount Dora Trust Investment Services now owns 25,288 shares of the medical instruments supplier’s stock worth $4,639,000 after buying an additional 4,839 shares during the period. Gulf International Bank UK Ltd increased its position in shares of Becton, Dickinson and by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 66,402 shares of the medical instruments supplier’s stock worth $12,180,000 after buying an additional 895 shares during the period. Finally, Union Bankshares Corp increased its position in shares of Becton, Dickinson and by 3.5% in the first quarter. Union Bankshares Corp now owns 21,954 shares of the medical instruments supplier’s stock worth $4,028,000 after buying an additional 743 shares during the period. 75.71% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded up 0.0454% during midday trading on Tuesday, reaching $197.9299. The company’s stock had a trading volume of 209,929 shares. The stock has a 50-day moving average price of $197.67 and a 200-day moving average price of $186.53. The stock has a market cap of $42.22 billion, a price-to-earnings ratio of 32.8733 and a beta of 1.05. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same period in the previous year, the business posted $2.35 earnings per share. The firm’s revenue for the quarter was down 5.1% compared to the same quarter last year. Equities research analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s dividend payout ratio is 83.43%.

COPYRIGHT VIOLATION NOTICE: This report was posted by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://baseballnewssource.com/markets/oppenheimer-asset-management-inc-takes-position-in-becton-dickinson-and-company-nysebdx/1408677.html.

A number of equities analysts have recently issued reports on the company. BidaskClub downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Sunday. Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday. Cowen and Company restated an “outperform” rating and set a $230.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. Bank of America Corporation restated a “buy” rating and set a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Finally, Royal Bank Of Canada restated a “hold” rating and set a $177.00 price objective on shares of Becton, Dickinson and in a research report on Thursday, April 13th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $194.69.

In other Becton, Dickinson and news, VP Jeffrey S. Sherman sold 28,765 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the completion of the sale, the vice president now directly owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with our FREE daily email newsletter.

 


Latest News

Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras


Leave a Reply

 
© 2006-2017 BBNS.